Literature DB >> 28920878

Edaravone for treatment of early-stage ALS - Authors' reply.

Makoto Akimoto1, Kazue Nakamura2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28920878     DOI： 10.1016/S1474-4422(17)30290-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

1.  ALS and CHARGE syndrome: a clinical and genetic study.

Authors:  Carmine Ungaro; Luigi Citrigno; Francesca Trojsi; Teresa Sprovieri; Giulia Gentile; Maria Muglia; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Sebastiano Cavallaro; Francesca Luisa Conforti
Journal:  Acta Neurol Belg       Date:  2018-10-13       Impact factor: 2.396

Review 2.  Existing and Emerging Metabolomic Tools for ALS Research.

Authors:  Christine Germeys; Tijs Vandoorne; Valérie Bercier; Ludo Van Den Bosch
Journal:  Genes (Basel)       Date:  2019-12-05       Impact factor: 4.096

3.  Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone.

Authors:  Eugenio Distaso; Giammarco Milella; Domenico Maria Mezzapesa; Alessandro Introna; Eustachio D'Errico; Angela Fraddosio; Stefano Zoccolella; Franca Dicuonzo; Isabella Laura Simone
Journal:  J Neurol       Date:  2021-03-02       Impact factor: 4.849

4.  Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.

Authors:  Qian Li; Yi Feng; Yingchao Xue; Xiping Zhan; Yi Fu; Gege Gui; Weiqiang Zhou; Jean-Philippe Richard; Arens Taga; Pan Li; Xiaobo Mao; Nicholas J Maragakis; Mingyao Ying
Journal:  Mol Neurodegener       Date:  2022-01-10       Impact factor: 14.195
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.